Michael A. Weber

A. Kirtane, M. Leon, R. Townsend, 2015, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

Renal Denervation for the Treatment of Hypertension: Making a New Start, Getting It Right

A. Kirtane, M. Leon, R. Townsend, 2015, Clinical cardiology.

International expert consensus statement: Percutaneous transluminal renal denervation for the treatment of resistant hypertension.

G. Parati, G. Mancia, G. Grassi, 2013, Journal of the American College of Cardiology.

May Measurement Month 2018: a pragmatic global screening campaign to raise awareness of blood pressure by the International Society of Hypertension

P. López-Jaramillo, D. Prabhakaran, E. O’Brien, 2019, European heart journal.

How Far to Reduce Blood Pressure in Patients With Diabetes—Even After ACCORD, Questions Remain

Michael A. Weber, 2010, Journal of clinical hypertension.

Beta-blocker therapy in hypertension: a need to pause and reflect.

G. Bakris, T. Giles, Michael A. Weber, 2008, Journal of the American College of Cardiology.

Amlodipine+Benazepril is Superior to Hydrochlorothiazide+Benazepril Irrespective of Baseline Pulse Pressure: Subanalysis of the ACCOMPLISH Trial

S. Kjeldsen, K. Jamerson, P. Svensson, 2015, Journal of clinical hypertension.

Outcomes of treating hypertension in the elderly: a short commentary on current issues.

Michael A. Weber, M. Weber, 2003, The American journal of geriatric cardiology.

Comparison of the Novel Angiotensin II Receptor Blocker Azilsartan Medoxomil vs Valsartan by Ambulatory Blood Pressure Monitoring

G. Bakris, Alfonso T. Perez, W. White, 2011, Journal of clinical hypertension.

Secondary analysis of the VALUE trial: Intriguing new questions

Michael A. Weber, M. Weber, 2007, Current hypertension reports.

New opportunities in cardiovascular patient management: a survey of clinical data on the combination of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.

Michael A. Weber, M. Weber, 2007, The American journal of cardiology.

The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) Trial: Outcomes in Patients Receiving Monotherapy

J. Laragh, A. Zanchetti, S. Kjeldsen, 2006, Hypertension.

The Importance of Prompt Blood Pressure Control to Target in High Risk Hypertensive Patients: The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial

S. Kjeldsen, S. Julius, G. Moe, 2004 .

Review: Angiotensin II receptor blockers and cardiovascular outcomes: what does the future hold?

Michael A. Weber, M. Weber, 2003, Journal of the renin-angiotensin-aldosterone system : JRAAS.

Fluvastatin Lipid-Lowering Effect in Routine Practice Conditions (FLIRT)

C. Pfafferott, Michael A. Weber, S. Beil, 1997 .

ONTARGET: Questions Asked, Questions Answered

Michael A. Weber, 2008, Journal of clinical hypertension.

Combining RAAS and calcium channel blockade: ACCOMPLISH in perspective

S. Oparil, S. Kjeldsen, K. Jamerson, 2008, Blood pressure.

The technical report on sodium intake and cardiovascular disease in low- and middle-income countries by the joint working group of the World Heart Federation, the European Society of Hypertension and the European Public Health Association.

A. Dominiczak, P. Whelton, S. Oparil, 2017, European heart journal.

Ambulatory heart rate reduction after catheter-based renal denervation in hypertensive patients not receiving anti-hypertensive medications: data from SPYRAL HTN-OFF MED, a randomized, sham-controlled, proof-of-concept trial

S. Pocock, M. Böhm, R. Townsend, 2019, European heart journal.

Effect of antihypertensive monotherapy and combination therapy on arterial distensibility and left ventricular mass.

Michael A. Weber, J. Neutel, David H. G. Smith, 2004, American journal of hypertension.

The potential role of nitric oxide in cardiovascular safety when treating patients with osteoarthritis and hypertension: a moderated panel discussion.

W. White, C. Pepine, Michael A. Weber, 2009, The American journal of medicine.

Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial

G. Bakris, B. Pitt, V. Shi, 2010, The Lancet.

Angiotensin-converting enzyme inhibitors and angioedema: estimating the risk.

F. Messerli, Michael A. Weber, M. Weber, 2008, Hypertension.

The Role of the Sympathetic Nervous System in the Control of Left Ventricular Mass in Hypertension

J. Drayer, Michael A. Weber, 1985 .

Mediators of Changes in Left Ventricular Mass During Antihypertensive Therapy

J. Gardin, J. Drayer, Michael A. Weber, 1983 .

Cardiovascular Risk Factor Profile of Hypertension: Therapeutic Approaches

Michael A. Weber, J. Neutel, David H. G. Smith, 1992 .

Clinical Pharmacology of Centrally Acting Antihypertensive Agents

Michael A. Weber, M. Weber, 1989, Journal of clinical pharmacology.

The Accuracy in Measurement of Blood Pressure (AIM‐BP) collaborative: Background and rationale

K. Asayama, A. Schutte, D. Lackland, 2019, Journal of clinical hypertension.

Outcome after out-of-hospital cardiac arrest in a physician-staffed emergency medical system according to the Utstein style.

C. Schmitt, A. Schömig, G. Ndrepepa, 2007, American heart journal.

Angiotensin II receptor blockers and cardiovascular outcomes: what does the future hold?

Michael A. Weber, 2003, Journal of the renin-angiotensin-aldosterone system : JRAAS.

Tej K. Khalsa, N. Cook, M. Woodward, 2017, Journal of Human Hypertension.

Use of an Olmesartan Medoxomil‐Based Treatment Algorithm for Hypertension Control

Michael A. Weber, J. Neutel, David H. G. Smith, 2004, Journal of clinical hypertension.

Quality of Life Measured in a Practice‐Based Hypertension Trial of an Angiotensin Receptor Blocker

G. Bakris, T. Giles, Michael A. Weber, 2003 .

Changes in albuminuria predict mortality and morbidity in patients with vascular disease.

S. Yusuf, P. Gao, G. Mancia, 2011, Journal of the American Society of Nephrology : JASN.

Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: The ACCOMPLISH Study

J. Tuomilehto, G. Bakris, B. Pitt, 2008, Blood pressure.

Clinical Experience with Perindopril in Elderly Hypertensive Patients

J. Cohn, S. Julius, Michael A. Weber, 2004, American journal of cardiovascular drugs : drugs, devices, and other interventions.

Cardiovascular outcomes at recommended blood pressure targets in middle-aged and elderly patients with type 2 diabetes mellitus and hypertension

G. Mancia, S. Kjeldsen, S. Julius, 2021, Blood pressure.

Cardiovascular outcomes at recommended blood pressure targets in middle-aged and elderly patients with type 2 diabetes mellitus compared to all middle-aged and elderly hypertensive study patients with high cardiovascular risk

G. Mancia, S. Kjeldsen, S. Julius, 2021, Blood pressure.

No evidence for a J-shaped curve in treated hypertensive patients with increased cardiovascular risk: The VALUE trial

G. Mancia, A. Zanchetti, S. Kjeldsen, 2016, Blood pressure.

Exceptional early blood pressure control rates: The ACCOMPLISH trial

W. Cushman, G. Bakris, B. Pitt, 2007, Blood pressure.

Antihypertensive Utility of Perindopril in a Large, General Practice‐Based Clinical Trial

J. Cohn, S. Julius, Michael A. Weber, 2005 .

Yet more hypertension guidelines: what do they add?

Michael A. Weber, M. Weber, 2003, Journal of hypertension.

The Losartan Intervention for Endpoint Reduction (LIFE) Trial—Have Angiotensin‐Receptor Blockers Come of Age?

D. Sica, Michael A. Weber, M. Weber, 2002, Journal of clinical hypertension.

Mild hypertension : from drug trials to practice

D. Ganten, Michael A. Weber, T. Strasser, 1987 .

Recently Published Hypertension Guidelines of the JNC 8 Panelists, the American Society of Hypertension/International Society of Hypertension and Other Major Organizations: Introduction to a Focus Issue of The Journal of Clinical Hypertension

Michael A. Weber, M. Weber, 2014, Journal of clinical hypertension.

A COMMENTARY ON THE 2013 ESH/ESC GUIDELINES FOR THE MANAGEMENT OF ARTERIAL HYPERTENSION

Michael A. Weber, 2014 .

Will the Systolic Blood Pressure Intervention Trial (SPRINT) change Treatment Targets in Hypertension

Michael A. Weber, C. Ram, M. Weber, 2016 .

Changes in 24-Hour Patterns of Blood Pressure in Hypertension Following Renal Denervation Therapy

K. Kario, A. Kirtane, M. Böhm, 2019, HYPERTENSION.

Twenty-Four-Hour Ambulatory Blood Pressure Reduction Patterns After Renal Denervation in the SPYRAL HTN-OFF MED Trial.

Manesh R. Patel, K. Kario, M. Böhm, 2018, Circulation.

Efficacy of a Once‐Daily Formulation of Carvedilol for the Treatment of Hypertension

G. Bakris, D. Sica, Michael A. Weber, 2006, Journal of clinical hypertension.

Long-Term Results up to 12 Months After Catheter-Based Alcohol-Mediated Renal Denervation for Treatment of Resistant Hypertension

R. Schmieder, S. Bertog, D. Kandzari, 2021, Circulation. Cardiovascular interventions.

Comparison of Effectiveness of Azilsartan Medoxomil and Olmesartan in Blacks Versus Whites With Systemic Hypertension.

W. Cushman, G. Bakris, W. White, 2018, The American journal of cardiology.

Addressing Gaps in Our Knowledge of the Angiotensin Receptor Blockers: Report of a Roundtable

Michael A. Weber, 2009 .

The diabetes subgroup baseline characteristics of the Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH) trial.

G. Bakris, B. Pitt, V. Shi, 2008, Journal of the cardiometabolic syndrome.

Progressive effects of valsartan compared with amlodipine in prevention of diabetes according to categories of diabetogenic risk in hypertensive patients: The VALUE trial

G. Mancia, A. Zanchetti, R. Schmieder, 2008, Blood pressure.

Progress in treating hypertension.

N. Wenger, Michael A. Weber, M. Weber, 2008, The American journal of geriatric cardiology.

Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: A hypertensive population at high cardiovascular risk

S. Nesbitt, G. Bakris, B. Pitt, 2007, Blood pressure.

Clinical Trials Report

D. Sica, Michael A. Weber, 2004 .

Hypertension, the Metabolic Syndrome, and the Risk of Developing Diabetes: Is It Time to Change the Guidelines?

Michael A. Weber, 2004, Journal of clinical hypertension.

Comparison of benazepril plus amlodipine or hydrochlorothiazide in high-risk patients with hypertension and coronary artery disease.

G. Bakris, B. Pitt, T. Hua, 2013, The American journal of cardiology.

Progress and Controversies: Treating Obesity and Insulin Resistance in the Context of Hypertension

J. McGill, S. Haffner, J. Sowers, 2009, Journal of clinical hypertension.

Changes in ventricular septal thickness during diuretic therapy

J. Gardin, W. Aronow, J. Drayer, 1982, Clinical pharmacology and therapeutics.

Angiotensin II receptor blockers and cardiovascular outcomes: The evidence now and in the future

Michael A. Weber, M. Weber, 2001, Journal of the renin-angiotensin-aldosterone system : JRAAS.

Strategies for prevention of cardiovascular disease in adults with hypertension

P. Whelton, G. Parati, D. Lackland, 2020, Journal of clinical hypertension.

The Combined Alpha‐ and Beta‐Adrenergic Blocker Labetalol and Propranolol in the Treatment of High Blood Pressure: Similarities and Differences

J. Drayer, Michael A. Weber, CAROL A. Kaufman, 1984, Journal of clinical pharmacology.

Efficacy and tolerability of tasosartan, a novel angiotensin II receptor blocker: Results from a 10-week, double-blind, placebo-controlled, dose-titration study

V. Buckalew, Michael A. Weber, J. Neutel, 1999 .

Building research capacity within cardiovascular disease prevention and management in low‐ and middle‐income countries: A collaboration of the US Centers for Disease Control and Prevention, the Lancet Commission on Hypertension Group, Resolve to Save Lives, and the World Hypertension League

D. Lackland, A. Moran, M. Olsen, 2021, Journal of clinical hypertension.

John Laragh and the renin thesis: creating a paradigm.

Michael A. Weber, 2014, American journal of hypertension.

Olmesartan‐based monotherapy vs combination therapy in hypertension: A meta‐analysis based on age and chronic kidney disease status

G. Bakris, P. Deedwania, Michael A. Weber, 2017, Journal of clinical hypertension.

Usefulness of heart rate to predict cardiac events in treated patients with high-risk systemic hypertension.

G. Mancia, A. Zanchetti, S. Kjeldsen, 2012, The American journal of cardiology.

MINERALOCORTICOIDS IN ESSENTIAL AND SECONDARY HYPERTENSION INTRODUCTION TO THE SYMPOSIUM

J. Drayer, Michael A. Weber, 1982 .

Aldosterone: Possible Roles in Sustaining Essential Hypertension and in Determining Response to Antihypertensive Treatment

Michael A. Weber, D. Hurlbut, Purdy Re, 1981 .

Long-term cardiovascular consequences of diuretics vs calcium channel blockers vs angiotensin-converting enzyme inhibitors.

F. Messerli, Michael A. Weber, M. Weber, 2003, JAMA.

Turning Attention to the Young

Michael A. Weber, 2011, Journal of clinical hypertension.

The Metabolic Syndrome—What Is It and How Should It Be Managed?

B. Falkner, M. Moser, Michael A. Weber, 2006, Journal of clinical hypertension.

Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial

Manesh R. Patel, Neha J. Pagidipati, J. Stehli, 2020, The Lancet.

Six-Month Results of Treatment-Blinded Medication Titration for Hypertension Control Following Randomization to Endovascular Ultrasound Renal Denervation or a Sham Procedure in the RADIANCE-HTN SOLO Trial.

A. Kirtane, R. Schmieder, J. Basile, 2019, Circulation.

Measurement of Blood Pressure in Clinical Practice.

D. Lackland, Michael A. Weber, M. Weber, 2021, The American journal of the medical sciences.

Renal denervation in hypertension patients: Proceedings from an expert consensus roundtable cosponsored by SCAI and NKF

R. Townsend, K. Ferdinand, D. Kandzari, 2021, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

Applicationsof AmbulatoryBloodPressureMonitoringin Clinical Practice

Michael A. Weber, J. Neutel, David H. G. Smith, 1991 .

Non-invasive automated blood pressure monitoring in ambulatory normotensive men

J. Drayer, Michael A. Weber, E. R. Chard, 1984 .

A strategy utilizing ambulatory monitoring and home and clinic blood pressure measurements to optimize the safety evaluation of noncardiovascular drugs with potential for hemodynamic effects: a report from the SYNERGY trial

W. White, C. Gratzke, S. Herschorn, 2018, Blood pressure monitoring.

Cardiovascular Safety of the β3‐Adrenoceptor Agonist Mirabegron and the Antimuscarinic Agent Solifenacin in the SYNERGY Trial

W. White, C. Gratzke, S. Herschorn, 2018, Journal of clinical pharmacology.

Quality of Life Measured in a Practice‐Based Hypertension Trial of an Angiotensin Receptor Blocker

G. Bakris, T. Giles, Michael A. Weber, 2003, Journal of clinical hypertension.

Improved Understanding of Renal Nerve Anatomy: An Opportunity to Enhance Denervation Treatment of Hypertension.

Michael A. Weber, J. Osborn, M. Weber, 2021, JACC. Cardiovascular interventions.

Massive Left Ventricular Mural Thrombosis With Consumption Coagulopathy in Congestive Heart Failure

Michael A. Weber, F. Hubbell, B. B. Megaffin, 2005 .

Effect of Heart Rate on the Outcome of Renal Denervation in Patients With Uncontrolled Hypertension.

K. Kario, M. Böhm, R. Townsend, 2021, Journal of the American College of Cardiology.

Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial

M. Uder, A. Cremer, P. Gosse, 2021, The Lancet.

Prioritized Endpoints for Device-Based Hypertension Trials: the Win Ratio Methodology.

S. Pocock, M. Böhm, M. Fahy, 2020, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

Predictors of blood pressure response to ultrasound renal denervation in the RADIANCE-HTN SOLO study

P. Gosse, A. Kirtane, P. Blankestijn, 2021, Journal of Human Hypertension.

P-255: Ambulatory blood pressure monitoring in the primary care setting: Assessment of therapy on circadian variation of blood pressure from the MICCAT-2 trial

G. Bakris, W. White, T. Giles, 2005 .

Hypertension in Asia 2021: A major contribution to worldwide understanding and management of hypertension

D. Lackland, Michael A. Weber, 2021, Journal of clinical hypertension.

SAFETY AND EFFICACY OF AGGRESSIVE BLOOD PRESSURE LOWERING AMONG PATIENTS WITH DIABETES: SUBGROUP ANALYSES FROM THE ONTARGET TRIAL

S. Yusuf, J. Pogue, P. Gao, 2009 .

Global cardiovascular disease prevention and management: A collaboration of key organizations, groups, and investigators in low‐ and middle‐income countries

T. Frieden, D. Lackland, A. Moran, 2020, Journal of clinical hypertension.

Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial.

Deepak L. Bhatt, G. Hankey, S. Steinhubl, 2007, Journal of the American College of Cardiology.

Baseline Characteristics and Early Blood Pressure Control in the CONVINCE Trial

P. Grambsch, A. Zanchetti, H. Black, 2001, Hypertension.

Achieving blood pressure goals: should angiotensin II receptor blockers become first-line treatment in hypertension?

Michael A. Weber, M. Weber, 2009, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

24-hour ambulatory blood pressure in the ACCOMPLISH trial.

G. Bakris, K. Jamerson, Michael A. Weber, 2010, The New England journal of medicine.

Ambulatory blood pressure monitoring after 1 year on valsartan or amlodipine-based treatment: a VALUE substudy

G. Mancia, T. Pickering, S. Kjeldsen, 2007, Journal of hypertension.

Nocturnal Home Blood Pressure Monitoring

K. Kario, G. Parati, K. Asayama, 2019, Updates in Hypertension and Cardiovascular Protection.

Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: the first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension.

G. Bakris, B. Pitt, C. Wun, 2004, American journal of hypertension.

P-373: A comparison of the effects of amlodipine 5 mg/benazepril 20 mg combination therapy to component monotherapy on arterial distensibilitly and left ventricular hypertrophy in patients with mild to moderate hypertension

Michael A. Weber, J. Neutel, David H. G. Smith, 2002 .

Effects of the Selective Aldosterone Blocker Eplerenone Versus the Calcium Antagonist Amlodipine in Systolic Hypertension

W. White, D. Duprez, Michael A. Weber, 2003, Hypertension.

Effects of treatment for hypertension on cognitive function in the elderly.

Michael A. Weber, 2006, Current hypertension reports.

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial

J. Laragh, A. Zanchetti, S. Kjeldsen, 2004, The Lancet.

Physician (investigator) inertia in apparent treatment-resistant hypertension – Insights from large randomized clinical trials. Lennart Hansson Memorial Lecture

S. Kjeldsen, S. Julius, B. Dahlöf, 2015, Blood pressure.

12-Month Results From the Unblinded Phase of the RADIANCE-HTN SOLO Trial of Ultrasound Renal Denervation.

P. Gosse, A. Kirtane, R. Schmieder, 2020, JACC. Cardiovascular interventions.

Optimum antihypertensive therapy: does adiposity matter?

S. Franklin, Michael A. Weber, M. Weber, 2015, The Lancet.

Treatment of elderly hypertensive patients with a delayed-release verapamil formulation in a community-based trial.

H. Black, F. Messerli, Michael A. Weber, 2004, The American journal of geriatric cardiology.

Automated Blood-Pressure Measurements in the Diagnosis of Mild Hypertension

J. Drayer, Michael A. Weber, D. Brewer, 1986 .

Angiotensin II Receptor Blockers

Michael A. Weber, M. Weber, 2001 .

The foundation role of beta blockers across the cardiovascular disease spectrum: a year 2009 update.

H. Black, B. Greenberg, Michael A. Weber, 2010, The American journal of medicine.

Diagnosis ofMildHypertension byAmbulatory BloodPressure Monitoring

Michael A. Weber, J. Neutel, Da Smith, 1994 .

A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.

Deepak L. Bhatt, G. Hankey, S. Steinhubl, 2005, American heart journal.

Repetitive Blood Pressure Measurements: Clinical Issues, Techniques, and Data Analysis

J. Drayer, Michael A. Weber, D. Brewer, 1987 .

Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program

Jaskaran Singh, E. Wajs, Michael A. Weber, 2020, CNS Drugs.

Treating hypertension: who speaks for the patient?

D. Lackland, Michael A. Weber, M. Weber, 2021, Journal of Human Hypertension.

Cardiovascular Benefits of Angiotensin Converting Enzyme Inhibition plus Calcium Channel Blockade in Patients Achieving Tight Blood Pressure Control and with Resistant Hypertension.

R. Brook, N. Kaciroti, G. Bakris, 2020, American journal of hypertension.

Association between exercise frequency with renal and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk

S. Yusuf, K. Sliwa, E. Lonn, 2022, Cardiovascular Diabetology.

Remembering Dr Marvin Moser

D. Lackland, Michael A. Weber, 2015, Journal of clinical hypertension.

Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial.

Peter Sleight, Janet Wittes, James D Neaton, 2003, JAMA.

Who is an expert? Reply

K. Kario, G. Parati, G. Mancia, 2017 .

Reducing cardiovascular and cerebral events

Michael A. Weber, 2002 .

Treatment of patients with hypertension and arthritis pain: new concepts.

Michael A. Weber, M. Weber, 2009, The American journal of medicine.

Divergent Results Using Clinic and Ambulatory Blood Pressures: Report of a Darusentan-Resistant Hypertension Trial

P. Sager, H. Krum, G. Bakris, 2010, Hypertension.

Reduced blood pressure-lowering effect of catheter-based renal denervation in patients with isolated systolic hypertension: data from SYMPLICITY HTN-3 and the Global SYMPLICITY Registry.

Deepak L. Bhatt, K. Kario, G. Mancia, 2016, European heart journal.

Impact of Renal Pelvic Denervation on Systemic Hemodynamics and Neurohumoral Changes in a Porcine Model

Brad S. Hubbard, Michael A. Weber, D. Hering, 2021, American Journal of Nephrology.

Inhibiting the renin-angiotensin system to prevent cardiovascular diseases: do we need a more comprehensive strategy?

T. Giles, Michael A. Weber, 2006, Reviews in cardiovascular medicine.

THE NITRIC OXIDE DONATOR NAPROXCINOD HAS BLOOD PRESSURE EFFECTS SIMILAR TO PLACEBO IN PATIENTS ON RENIN-ANGIOTENSIN SYSTEM BLOCKERS: 9D.02

T. Schnitzer, W. White, Michael A. Weber, 2010 .

Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial

Neil Chapman, Manish Saxena, Jai Radhakrishnan, 2018, The Lancet.

Hypertension research from Japan: advancing the field of renal denervation

Michael A. Weber, M. Weber, 2021, Hypertension Research.

Expanding the opportunities for blocking the renin-angiotensin system: introduction to a special supplement.

Michael A. Weber, 2007, Reviews in cardiovascular medicine.

Adherence and persistence with taking medication to control high blood pressure.

S. Oparil, H. Black, J. Izzo, 2011, Journal of the American Society of Hypertension : JASH.

Association of beta-blocker use with increased aortic wave reflection.

L. Salciccioli, J. Lazar, Michael A. Weber, 2008, Journal of the American Society of Hypertension : JASH.

Building the case for central blood pressure.

R. Townsend, Michael A. Weber, M. Weber, 2013, Journal of the American College of Cardiology.

Systolic blood pressure and cardiovascular outcomes during treatment of hypertension.

G. Bakris, B. Pitt, T. Hua, 2013, The American journal of medicine.

Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients.

G. Bakris, B. Pitt, V. Shi, 2008, The New England journal of medicine.

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The value randomised trial☆

S. Kjeldsen, S. Julius, Michael A. Weber, 2004 .

The Antihypertensive Efficacy and Safety of a Chronotherapeutic Formulation of Propranolol in Patients With Hypertension

D. Sica, Michael A. Weber, J. Neutel, 2004, The Journal of Clinical Hypertension.

Evaluation of the 24 h effects of the angiotensin II receptor blockers: means to improve cardiovascular outcomes?

W. White, Michael A. Weber, M. Weber, 2003, Blood pressure monitoring.

Calcium Channel Antagonists in the Treatment of Hypertension

Michael A. Weber, M. Weber, 2002, American journal of cardiovascular drugs : drugs, devices, and other interventions.

Interrupting the renin-angiotensin system: the role of angiotensin-converting enzyme inhibitors and angiotensin ii receptor antagonists in the treatment of hypertension

Michael A. Weber, M. Weber, 1999 .

Global burden of cardiovascular disease and stroke: hypertension at the core.

D. Lackland, Michael A. Weber, Daniel T Lackland, 2015, The Canadian journal of cardiology.